This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by ERIKSEN, E. F. Search for Related Content PubMed PubMed Citation Articles by ERIKSEN, E. F. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CALCIUM COMPOUNDS CALCIUM, ELEMENTAL

Normal and Pathological Remodeling of Human Trabecular Bone: Three Dimensional Reconstruction of the Remodeling Sequence in Normals and in Metabolic Bone Disease^*

Medical Department III, Division of Endocrinology and Metabolism and University Institute of Pathology Aarhus Amtssygehus, DK-8000 Aarhus, Denmark

Correspondence: Address requests for reprints to: Dr. E. F. Eriksen, Endocrine Research Unit, Mayo Clinic, Mayo Foundation 5-164, West Joseph, Set. Marys Hospital, Rochester, Minnesota 55905.

Abstract

Introduction: THE INTRODUCTION of the quantum concept for bone remodeling and in vivo tetracycline labeling by Frost in 1964 (1–3) has had a profound impact on histological studies of metabolic bone diseases over the last two decades. The quantum concept implies that changes in bone mass result from an imbalance between the amount of bone resorbed and formed, leading to either loss or gain of bone during the continuous remodeling of adult bone (1–3). Recently, a new dimension to the theories on bone loss emphasizing the importance of trabecular perforations in the development of osteopenia has been introduced by Parfitt (4). This theory explains the profound disintegration of the trabecular network occurring in certain disease states characterized by high bone turnover and increased resorptive activity (e.g. postmenopausal osteoporotic women with spontaneous vertebral fractures) and may also explain part of the bone loss that occurs with increasing age.

Footnotes

^* Supported by grants from the Institute of Clinical Experimental Research, University of Aarhus, L. F. Foghts Fond, and Novos Fond.

This article has been cited by other articles:

				M. L. Brandi Microarchitecture, the key to bone quality Rheumatology, October 1, 2009; 48(suppl_4): iv3 - iv8. [Abstract] [Full Text] [PDF]

				T. L. Andersen, T. E. Sondergaard, K. E. Skorzynska, F. Dagnaes-Hansen, T. L. Plesner, E. M. Hauge, T. Plesner, and J.-M. Delaisse A Physical Mechanism for Coupling Bone Resorption and Formation in Adult Human Bone Am. J. Pathol., January 1, 2009; 174(1): 239 - 247. [Abstract] [Full Text] [PDF]

				B. Clarke Normal Bone Anatomy and Physiology Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(Supplement_3): S131 - S139. [Abstract] [Full Text] [PDF]

				A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]

				L. C. Gerstenfeld, Y. M. Alkhiary, E. A. Krall, F. H. Nicholls, S. N. Stapleton, J. L. Fitch, M. Bauer, R. Kayal, D. T. Graves, K. J. Jepsen, et al. Three-dimensional Reconstruction of Fracture Callus Morphogenesis J. Histochem. Cytochem., November 1, 2006; 54(11): 1215 - 1228. [Abstract] [Full Text] [PDF]

				H. Dobnig, A. Sipos, Y. Jiang, A. Fahrleitner-Pammer, L.-G. Ste-Marie, J. C. Gallagher, I. Pavo, J. Wang, and E. F. Eriksen Early Changes in Biochemical Markers of Bone Formation Correlate with Improvements in Bone Structure during Teriparatide Therapy J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3970 - 3977. [Abstract] [Full Text] [PDF]

				Y. M. Alkhiary, L. C. Gerstenfeld, E. Krall, M. Westmore, M. Sato, B. H. Mitlak, and T. A. Einhorn Enhancement of Experimental Fracture-Healing by Systemic Administration of Recombinant Human Parathyroid Hormone (PTH 1-34) J. Bone Joint Surg. Am., April 1, 2005; 87(4): 731 - 741. [Abstract] [Full Text] [PDF]

				R. J Dansereau and D. J Crail Extemporaneous Procedures for Dissolving Risedronate Tablets for Oral Administration and for Feeding Tubes Ann. Pharmacother., January 1, 2005; 39(1): 63 - 67. [Abstract] [Full Text] [PDF]

				S. T. Harris, E. F. Eriksen, M. Davidson, M. P. Ettinger, A. H. Moffett Jr., D. J. Baylink, C. E. Crusan, and A. A. Chines Effect of Combined Risedronate and Hormone Replacement Therapies on Bone Mineral Density in Postmenopausal Women J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1890 - 1897. [Abstract] [Full Text]

				G. Khastgir, J. Studd, N. Holland, J. Alaghband-Zadeh, S. Fox, and J. Chow Anabolic Effect of Estrogen Replacement on Bone in Postmenopausal Women with Osteoporosis: Histomorphometric Evidence in a Longitudinal Study J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 289 - 295. [Abstract] [Full Text]

				H. Pantazi and P. D. Papapetrou Changes in Parameters of Bone and Mineral Metabolism during Therapy for Hyperthyroidism J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1099 - 1106. [Abstract] [Full Text]

				L. G. Raisz Physiology and Pathophysiology of Bone Remodeling Clin. Chem., August 1, 1999; 45(8): 1353 - 1358. [Abstract] [Full Text] [PDF]

				S. L. Greenspan and F. S. Greenspan The Effect of Thyroid Hormone on Skeletal Integrity Ann Intern Med, May 4, 1999; 130(9): 750 - 758. [Abstract] [Full Text] [PDF]

				J. R. Hartke Preclinical Development of Agents for the Treatment of Osteoporosis Toxicol Pathol, January 1, 1999; 27(1): 143 - 147. [Abstract] [PDF]

				R. Eastell Treatment of Postmenopausal Osteoporosis N. Engl. J. Med., March 12, 1998; 338(11): 736 - 746. [Full Text] [PDF]

				A. G. Johansson, E. F. Eriksen, E. Lindh, B. Langdahl, W. F. Blum, A. Lindahl, O. Ljunggren, and S. Ljunghall Reduced Serum Levels of the Growth Hormone-Dependent Insulin-Like Growth Factor Binding Protein and a Negative Bone Balance at the Level of Individual Remodeling Units in Idiopathic Osteoporosis in Men J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2795 - 2798. [Abstract] [Full Text] [PDF]

				E. Jodar, M. Munoz-Torres, F. Escobar-Jimenez, M. Quesada, J. D. Luna, and N. Olea Antiresorptive Therapy in Hyperthyroid Patients: Longitudinal Changes in Bone and Mineral Metabolism J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1989 - 1994. [Abstract] [Full Text] [PDF]

				H. G. Bone, R. W. Downs Jr., J. R. Tucci, S. T. Harris, R. S. Weinstein, A. A. Licata, M. R. McClung, D. B. Kimmel, B. J. Gertz, E. Hale, et al. Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 265 - 274. [Abstract] [Full Text] [PDF]

				L. Wartofsky Levothyroxine Therapy and Osteoporosis: An End to the Controversy? Arch Intern Med, June 12, 1995; 155(11): 1130 - 1131. [Abstract] [PDF]